Suppr超能文献

经导管主动脉瓣置换术(TAVR)后起搏器的预测因素和 5 年临床结局:来自 PARTNER 2 SAPIEN 3 注册研究的分析。

Predictors and 5-Year Clinical Outcomes of Pacemaker After TAVR: Analysis From the PARTNER 2 SAPIEN 3 Registries.

机构信息

Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, New York, USA.

Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.

出版信息

JACC Cardiovasc Interv. 2024 Jun 10;17(11):1325-1336. doi: 10.1016/j.jcin.2024.03.034.

Abstract

BACKGROUND

Conduction disturbances requiring a permanent pacemaker (PPM) are a frequent complication of transcatheter aortic valve replacement (TAVR) with few reports of rates, predictors, and long-term clinical outcomes following implantation of the third-generation, balloon-expandable SAPIEN 3 (S3) transcatheter heart valve (THV).

OBJECTIVES

The aim of this study was to investigate the rates, predictors, and long-term clinical outcomes of PPM implantation following TAVR with the S3 THV.

METHODS

The current study included 857 patients in the PARTNER 2 S3 registries with intermediate and high surgical risk without prior PPM, and investigated predictors and 5-year clinical outcomes of new PPM implanted within 30 days of TAVR.

RESULTS

Among 857 patients, 107 patients (12.5%) received a new PPM within 30 days after TAVR. By multivariable analysis, predictors of PPM included increased age, pre-existing right bundle branch block, larger THV size, greater THV oversizing, moderate or severe annulus calcification, and implantation depth >6 mm. At 5 years (median follow-up 1,682.0 days [min 2.0 days, max 2,283.0 days]), new PPM was not associated with increased rates of all-cause mortality (Adj HR: 1.20; 95% CI: 0.85-1.70; P = 0.30) or repeat hospitalization (Adj HR: 1.22; 95% CI: 0.67-2.21; P = 0.52). Patients with new PPM had a decline in left ventricular ejection fraction at 1 year that persisted at 5 years (55.1 ± 2.55 vs 60.4 ± 0.65; P = 0.02).

CONCLUSIONS

PPM was required in 12.5% of patients without prior PPM who underwent TAVR with a SAPIEN 3 valve in the PARTNER 2 S3 registries and was not associated with worse clinical outcomes, including mortality, at 5 years. Modifiable factors that may reduce the PPM rate include bioprosthetic valve oversizing, prosthesis size, and implantation depth.

摘要

背景

经导管主动脉瓣置换术(TAVR)后常发生需要植入永久性起搏器(PPM)的传导障碍,仅有少数研究报告了第三代球囊扩张型 SAPIEN 3(S3)经导管心脏瓣膜(THV)植入后的发生率、预测因素和长期临床结局。

目的

本研究旨在探讨 S3 THV 行 TAVR 后 PPM 植入的发生率、预测因素和长期临床结局。

方法

本研究纳入了 PARTNER 2 S3 注册研究中 857 例无既往 PPM 的中高危外科手术患者,研究了 TAVR 后 30 天内植入新的 PPM 的预测因素和 5 年临床结局。

结果

在 857 例患者中,107 例(12.5%)在 TAVR 后 30 天内植入了新的 PPM。多变量分析显示,PPM 的预测因素包括年龄增加、术前右束支传导阻滞、THV 尺寸较大、THV 过度扩张、中度或重度瓣环钙化以及植入深度>6mm。5 年(中位随访时间 1682.0 天[最短 2.0 天,最长 2283.0 天])时,新 PPM 与全因死亡率增加无关(调整 HR:1.20;95%CI:0.85-1.70;P=0.30)或重复住院率增加无关(调整 HR:1.22;95%CI:0.67-2.21;P=0.52)。植入新 PPM 的患者左心室射血分数在 1 年时下降,5 年后仍持续下降(55.1±2.55 比 60.4±0.65;P=0.02)。

结论

PARTNER 2 S3 注册研究中,857 例无既往 PPM 的患者行 S3 瓣膜 TAVR 后,有 12.5%的患者需要植入 PPM,5 年时,PPM 与死亡率等临床结局较差无关。可能降低 PPM 发生率的可改变因素包括生物瓣过度扩张、瓣膜尺寸和植入深度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验